We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fresh Guidelines Issued for Red Blood Cell Transfusion

By LabMedica International staff writers
Posted on 09 Apr 2012
Print article
Wide variability in the use of transfusions in the United States indicates that in many settings patients are receiving unnecessary transfusions.

Evidence shows no difference in mortality, ability to walk independently, or length of hospital stay between patients on a liberal transfusion strategy or a restrictive strategy of red blood cell transfusions.

The AABB (formerly known as the American Association of Blood Banks; Bethesda, MD, USA), has recently updated its guidelines for a red blood cell transfusion strategy for stable adults and children. A 20-member panel of experts based their assessment on a systematic review of research published from 1950 to 2011 to determine optimal use of red blood cells to maximize clinical outcomes and avoid the harms and costs of unnecessary transfusions.

The panel examined the proportion of patients who received any red cell transfusion and the number of red cell units transfused to describe the impact of restrictive transfusion strategies on red blood cell usage. To determine the clinical consequences of a restrictive strategy, the scientists examined overall mortality, nonfatal myocardial infarction, cardiac events, pulmonary edema, stroke, thromboembolism, renal failure, infection, hemorrhage, mental confusion, functional recovery, and length of hospital stay.

They recommended that physicians should consider transfusing at a hemoglobin threshold of 7 to 8 g/dL. Physicians should also consider transfusion for patients with symptoms of anemia or a hemoglobin of less than or equal to 8 g/dL. However, the researchers caution that there was some uncertainty about risk for perioperative myocardial infarction associated with this approach. The panel found insufficient evidence to recommend a liberal or restrictive transfusion strategy for patients with acute coronary syndrome. While physicians most commonly use hemoglobin concentration to decide when to transfuse, the panel suggests that physicians also consider symptoms of anemia in their decision-making.

Jeffrey L. Carson, MD, from the Robert Wood Johnson Medical School, (New Brunswick, NJ, USA), and lead author of the guidelines, said, "Our recommendation is based on the evidence that restrictive transfusion is safe and associated with less blood use. Of course, clinical judgment is critical.

Physicians may choose to transfuse above or below the specified hemoglobin threshold based on individual patient characteristics.” Darrell J. Triulzi, MD, the president of AABB, added, "AABB believes that hospitals and clinicians can reduce the number of unnecessary transfusions. Implementing evidence-based transfusion is perhaps the most important step hospitals can take to achieve this goal." The guidelines were published in the March 26, 2012, online edition of the Annals of Internal Medicine.

Related Links:

AABB


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Centromere B Assay
Centromere B Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.